FDA staff argue Avastin benefit in breast cancer not worth the risk
This article was originally published in Scrip
At the first day - 28 June - of the much-anticipated two-day hearing on whether the USFDA should no longer allow Avastin (bevacizumab) from Roche's US arm Genentech to be sold for use in combination with paclitaxel to treat metastatic HER2 negative breast cancer, officials from the agency's Center for Drug Evaluation and Research (CEDR) made much the same arguments they advanced last July in persuading a panel of outside experts to recommend that the indication be dropped (scripintelligence.com, 21 July 2010).
You may also be interested in...
Novo Nordisk’s bid to get marketing approval from the US FDA for the company’s new long-lasting insulin got a lukewarm endorsement on 8 November from the agency’s panel of outside experts.
The US FDA's cardiovascular and renal drugs advisory committee on January 11th unanimously recommended to the agency that it not approve Forest Laboratories' application to market its beta blocker nebivolol as a treatment for chronic heart failure (CHF).
Although the US Congress is technically in recess – the House of Representatives until January 12th and the Senate until January 19th – key lawmakers got down to work the week commencing January 4th, trying to hammer out the differences between the versions of health reform legislation passed by the two bodies. Only when the two vote in support of identical language can the measure move to President Barack Obama to be signed into law. The goal is to get that done by the end of this month, but it is not a firm deadline and the final votes may slip into February.